News

The drug is a novel, oral formulation of carbidopa/levodopa (CD/LD) in extended release capsules, intended for the treatment ofParkinson’sdiseasecurrentlyunderreview by the US Food and Drug Administration (FDA). It is expected that Zambon will seek regulatory approval and commercialise the drug in Europe.

Financial terms of the agreement have not been disclosed.

This ‘announcement of a licensing agreement with a European partner is part of Amneal’s broader strategy to bring IPX203 to Parkinson’s patients around the world. Earlier this year, Amneal also signed a license agreement with Knight Therapeutics Inc. granting exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America’, according to the company’s press release.

Chirag and Chintu Patel, co-chief executive officers at Amneal, commented: “We believe IPX203 can improve the lives of the more than ten million people worldwide living with Parkinson’s disease. It has been a strategic goal of Amneal to ensure that not only US patients, but also Parkinson’s patients worldwide have access to our products. Zambon, a family-owned business with whom we share a long-term vision and commitment toward patient communities, is the right partner to extend the reach of IPX203 to Europe.”

Frank Weber, chief executive officer at Zambon Biotech, added: “Zambon Biotech’s mission is to build a long-term pipeline of innovative medicines that make patients’ lives better. Given our group’s capabilities in commercialisation and our existing footprint in neurology, particularly Parkinson’s, we are pleased to partner with Amneal to bring IPX203 to Parkinson’s patients in Europe.”